Cancer treatment has been promoted to target recurrent or refractory large B-cell lymphoma by introducing a novel therapy using off-the-shelf anti-CD19 CAR-engineered double-negative T cells (RJMTY19). This innovative approach aims to overcome the limitations of traditional autologous CAR-T cell therapies, which are often expensive, time-consuming and inaccessible to many patients.
A research team led by Dr. Liming Yang, PhD, of the Department of Hematology, the second affiliated hospital, the School of Medicine of Zhige University and Wyze Biotech Co. Ltd., whose colleagues conducted the Phase 1, Phase 1 clinical trial to evaluate The safety and efficacy of this innovative treatment. Their work was published in the peer-reviewed journal Eclinicalmedicine.
The study recruited a small group of patients with relapsed or refractory B-cell lymphoma who received multiple previous treatments. These patients received a single dose of RJMTY19 after receiving lymphadenogenic chemotherapy. The researchers evaluated different dose levels to determine the optimal dose. It is worth noting that this trial did not find toxicity of the restricted dose, indicating good safety.
In terms of efficacy, the highest dose levels showed impressive results. Dr. Yang stressed the importance of these findings: “Our results show that CD19-Car-DNT cells appear to be well tolerated in antitumor activity in LBCL patients. It is necessary to further study the sample size of this product.
Notably, the study reported overall positive reactions and saw significant benefits at higher doses. Patients receiving the highest doses show the greatest benefit, and all patients at these levels can obtain disease control and objective responses. This dose-dependent efficacy is a crucial finding that underlines the potential of RJMTY19 as a viable therapeutic option for patients with large B-cell lymphomas.
The researchers observed that the most common adverse reaction of treatments is hematologic toxicity, including a decrease in certain blood cell counts, which are easy to manage and can be expected. Importantly, there is no severe cytokine release syndrome (CRS) or immune effector cell-associated neurotoxic syndrome (ICAN), which is often a focus of CAR-T therapy.
Dr. Yang highlighted the potential impact of their work: “This phase 1 trial is a critical step in providing accessible effective treatment for patients with relapsed or refractory large B-cell lymphoma. Promising results need to be found in larger clinical settings Further research in the experiment.”
The findings of the study suggest that RJMTY19 can revolutionize the treatment situation in large B-cell lymphomas by providing more accessible and more effective options than current therapies. As researchers move forward in large-scale trials, the oncology community is eagerly awaiting further validation of these promising results.
In summary, this study by Dr Qian and Dr Yang, along with other experts, offers hope for patients with relapsed or refractory large B-cell lymphoma, highlighting the potential of CD19-CAR-DNT cells as a new field of cancer immunotherapy. The study paves the way for future advancement and emphasizes the importance of innovative approaches in fighting cancer.
Journal Reference
Xibin Xiao, Hui Liu, Xi Qiu, Panpan Chen, Xian Li, Dan Wang, Guangrong Song, Yu Cheng, Liming Yang and Wenbin Qian. “CD19-CAR-DNT cells (RJMTY19) in patients with relapsed or refractory large B-cell lymphoma: Phase 1, human research.” Eclinicalmedicine, 2024. Doi:
About the Author
Dr. Liming Yang is the co-founder and chairman of Wyze Biotech Co., Ltd, a Chinese-based clinic stage company, who is engaged in the development and commercialization of new ready-made allogeneic DNT (double negative T) cell immunotherapy. There are now five first-class and first phase I/II clinical trials for the treatment of Chinese hematological malignancies and autoimmune diseases, and show promising safety and effectiveness. Dr. Yang has published more than 30 papers in peer-reviewed journals and is the inventor of more than 10 patent applications in the field of DNT technology.
April 28, 2024
